Elafibranor - Moligand™, 10mM in DMSO , Agonist of Peroxisome proliferator-activated receptor-α;Agonist of Peroxisome proliferator-activated receptor-γ, CAS No.923978-27-2, Agonist of Peroxisome proliferator-activated receptor-α;Agonist of Peroxisome proliferator-activated receptor-γ

CAS: 923978-27-2 Cat. No.: E408744 Summenformel: C₂₂H₂₄O₄S Molekulargewicht: 384.49 EG-Nummer: 815-538-9

QUALITÄT & REINHEIT Moligand™, 10mM in DMSO

Synonyms

GFT505 | Propanoic acid, 2-​[2,​6-​dimethyl-​4-​[(1E)​-​3-​[4-​(methylthio)​phenyl]​-​3-​oxo-​1-​propen-​1-​yl]​phenoxy]​-​2-​methyl-

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Übersicht

Information

Elafibranor (GFT505) is an agonist of theperoxisome proliferator-activated receptor-α(PPAR-alpha)andperoxisome proliferator-activated receptor-δ(PPAR-δ). It improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation.
In vitro

GFT505 is a novel PPAR modulator that shows a preferential activity on PPAR-α and concomitant activity on PPAR-δ.

In vivo

Elafibranor (GFT505) is a dual PPARα/δ agonist that has demonstrated efficacy in disease models of nonalcoholic fatty liver disease (NAFLD)/NASH and liver fibrosis. In the rat, GFT505 concentrated in the liver with limited extrahepatic exposure and underwent extensive enterohepatic cycling. Elafibranor confers liver protection by acting on several pathways involved in NASH pathogenesis, reducing steatosis, inflammation, and fibrosis. GFT505 improved liver dysfunction markers, decreased hepatic lipid accumulation, and inhibited proinflammatory (interleukin-1 beta, tumor necrosis factor alpha, and F4/80) and profibrotic (transforming growth factor beta, tissue inhibitor of metalloproteinase 2, collagen type I, alpha 1, and collagen type I, alpha 2) gene expression.
Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥98%

Spezifikationen

Synonyme

GFT505 | Propanoic acid, 2-​[2,​6-​dimethyl-​4-​[(1E)​-​3-​[4-​(methylthio)​phenyl]​-​3-​oxo-​1-​propen-​1-​yl]​phenoxy]​-​2-​methyl-

Spezifikationen & Reinheit

Moligand™, 10mM in DMSO

Biochemische und physiologische Mechanismen

Elafibranor (GFT505) is an agonist of the peroxisome proliferator-activated receptor-α(PPAR-alpha) and peroxisome proliferator-activated receptor-δ(PPAR-δ). It improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammatio

Storage

Store at -80°C

Verschickt in

Dry ice packs + Cold packs

Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.

Note

Moligand™

Aktionsart

AGONIST

Mechanismus der Wirkung

Agonist of Peroxisome proliferator-activated receptor-α;Agonist of Peroxisome proliferator-activated receptor-γ

Produkteigenschaften

ALogP

5.477

hba_count

3

Rotationsfähige Bindung

7

Namen und Kennungen

Isomere SMILES

CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)/C=C/C(=O)C2=CC=C(C=C2)SC

Molekulargewicht

384.49

Reaxy-Rn

24554260

Reaxys-RN_link_address

https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=24554260&ln=

Zugehörige Ziele (menschlich)

PPARA Tclin Peroxisome proliferator-activated receptor alpha (0 Activities)

Discover Target: PPARA

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PPARD Tchem Peroxisome proliferator-activated receptor delta (0 Activities)

Discover Target: PPARD

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Chemische und physikalische Eigenschaften

• Löslichkeit: Solubility (25°C) In vitro DMSO: 29 mg/mL (195.68 mM)
• DMSO (mg/ml) Maximale Löslichkeit: 76
• DMSO (mM) Maximale Löslichkeit: 197.6644386
• Wasser (mg/ml) Maximale Löslichkeit: ＜1